Suppr超能文献

靶向Notch信号通路以克服癌症治疗中的耐药性。

Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.

作者信息

Wang Zhiwei, Li Yiwei, Ahmad Aamir, Azmi Asfar S, Banerjee Sanjeev, Kong Dejuan, Sarkar Fazlul H

机构信息

Department of Pathology, Karmanos Cancer Institute, Wayne State University, School of Medicine, Detroit, MI 48201, USA.

出版信息

Biochim Biophys Acta. 2010 Dec;1806(2):258-67. doi: 10.1016/j.bbcan.2010.06.001. Epub 2010 Jun 22.

Abstract

Chemotherapy is an important therapeutic strategy for cancer treatment and remains the mainstay for the management of human malignancies; however, chemotherapy fails to eliminate all tumor cells because of intrinsic or acquired drug resistance, which is the most common cause of tumor recurrence. Recently, emerging evidences suggest that Notch signaling pathway is one of the most important signaling pathways in drug-resistant tumor cells. Moreover, down-regulation of Notch pathway could induce drug sensitivity, leading to increased inhibition of cancer cell growth, invasion, and metastasis. This article will provide a brief overview of the published evidences in support of the roles of Notch in drug resistance and will further summarize how targeting Notch by "natural agents" could become a novel and safer approach for the improvement of tumor treatment by overcoming drug resistance.

摘要

化疗是癌症治疗的重要策略,仍是人类恶性肿瘤治疗的主要手段;然而,由于内在或获得性耐药,化疗无法清除所有肿瘤细胞,这是肿瘤复发的最常见原因。最近,越来越多的证据表明,Notch信号通路是耐药肿瘤细胞中最重要的信号通路之一。此外,Notch通路的下调可诱导药物敏感性,导致对癌细胞生长、侵袭和转移的抑制作用增强。本文将简要概述已发表的支持Notch在耐药中作用的证据,并进一步总结通过“天然药物”靶向Notch如何可能成为一种新颖且更安全的方法,通过克服耐药性来改善肿瘤治疗。

相似文献

1
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.
Biochim Biophys Acta. 2010 Dec;1806(2):258-67. doi: 10.1016/j.bbcan.2010.06.001. Epub 2010 Jun 22.
2
Downregulation of Notch Signaling Pathway as an Effective Chemosensitizer for Cancer Treatment.
Drug Res (Stuttg). 2016 Nov;66(11):571-579. doi: 10.1055/s-0042-111821. Epub 2016 Oct 4.
4
Targeting Notch signaling pathway as an effective strategy in overcoming drug resistance in ovarian cancer.
Pathol Res Pract. 2020 Nov;216(11):153158. doi: 10.1016/j.prp.2020.153158. Epub 2020 Aug 9.
5
Trastuzumab resistance: role for Notch signaling.
ScientificWorldJournal. 2009 Dec 16;9:1438-48. doi: 10.1100/tsw.2009.166.
6
Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence.
Br J Cancer. 2011 Sep 6;105(6):796-806. doi: 10.1038/bjc.2011.321. Epub 2011 Aug 16.
7
[Gemcitabine and breast cancer].
Bull Cancer. 2002 Aug;89 Spec No:S107-14.
8
Regulation of EMT by Notch signaling pathway in tumor progression.
Curr Cancer Drug Targets. 2013 Nov;13(9):957-62. doi: 10.2174/15680096113136660101.
9
Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer.
Arch Med Res. 2014 Jan;45(1):15-20. doi: 10.1016/j.arcmed.2013.10.001. Epub 2013 Dec 5.
10
Rational targeting of Notch signaling in cancer.
Oncogene. 2008 Sep 1;27(38):5124-31. doi: 10.1038/onc.2008.226.

引用本文的文献

5
The role of miR-92b-3p in notch signaling and monitoring of oral squamous cell carcinoma.
Oncogene. 2025 May;44(18):1300-1311. doi: 10.1038/s41388-025-03306-2. Epub 2025 Feb 18.
9
Transcriptome analysis reveals PRKCA as a potential therapeutic target for overcoming cisplatin resistance in lung cancer through ferroptosis.
Heliyon. 2024 May 7;10(10):e30780. doi: 10.1016/j.heliyon.2024.e30780. eCollection 2024 May 30.
10
A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma.
Haematologica. 2024 Aug 1;109(8):2606-2618. doi: 10.3324/haematol.2023.284443.

本文引用的文献

1
Notch-1 and notch-4 receptors as prognostic markers in breast cancer.
Int J Surg Pathol. 2011 Oct;19(5):607-13. doi: 10.1177/1066896910362080. Epub 2010 May 5.
3
Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes.
Gynecol Oncol. 2010 Jun;117(3):409-16. doi: 10.1016/j.ygyno.2010.03.004. Epub 2010 Mar 31.
4
Implication of microRNAs in drug resistance for designing novel cancer therapy.
Drug Resist Updat. 2010 Jun;13(3):57-66. doi: 10.1016/j.drup.2010.02.001. Epub 2010 Mar 17.
6
Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer.
Am J Pathol. 2010 Apr;176(4):2019-28. doi: 10.2353/ajpath.2010.090908. Epub 2010 Feb 18.
8
The role of MAP kinases and MAP kinase phosphatase-1 in resistance to breast cancer treatment.
Cancer Metastasis Rev. 2010 Mar;29(1):143-9. doi: 10.1007/s10555-010-9208-5.
9
Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.
J Clin Oncol. 2010 Mar 1;28(7):1254-61. doi: 10.1200/JCO.2009.24.6116. Epub 2010 Jan 25.
10
Notch-1 inhibition by Withaferin-A: a therapeutic target against colon carcinogenesis.
Mol Cancer Ther. 2010 Jan;9(1):202-10. doi: 10.1158/1535-7163.MCT-09-0771. Epub 2010 Jan 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验